Literature DB >> 8536722

Nontuberculous mycobacterial infection in HIV-negative patients receiving immunosuppressive therapy.

K Skogberg1, P Ruutu, P Tukiainen, V V Valtonen.   

Abstract

The clinical significance of nontuberculous mycobacterial isolates and presentation of mycobacteriosis was compared in HIV-negative patients with or without preceding immunosuppression. Patients with nontuberculous mycobacterial isolates (n = 139), mainly from the respiratory system, were divided into three groups: those who had had previous immunosuppressive treatment (24%), those with other underlying diseases (54%) and those without predisposing factors (22%). The distribution of mycobacterial species among the various patient groups was similar. The immunosuppressed patients fulfilled the criteria of the American Thoracic Society for clinical mycobacteriosis less frequently (18%) than those with other underlying diseases (32%) or without predisposing factors (45%), p = 0.07, the difference being more striking for patients with Mycobacterium avium complex isolates. This was partly due to the difficulty in distinguishing the relevant symptoms from those caused by the underlying disease. The proportion of patients receiving antimycobacterial therapy differed similarly (18%, 21%, 45%, respectively). Among the immunosuppressed patients, positive acid-fast smears were significantly less common and polymicrobial infections, initial lymphocytopenia, fever and fatal outcome significantly more common. About half of the immunosuppressed patients died within one year. In order to better define patients requiring treatment, the criteria for localized mycobacteriosis among immunosuppressed patients should be reevaluated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536722     DOI: 10.1007/bf01690989

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  39 in total

Review 1.  Agents of newly recognized or infrequently encountered mycobacterial diseases.

Authors:  L G Wayne; H A Sramek
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

Review 2.  Immune mechanisms in the pathogenesis of pulmonary tuberculosis.

Authors:  A M Dannenberg
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr

3.  Tuberculosis complicating neoplastic disease. A review of 201 cases.

Authors:  M H Kaplan; D Armstrong; P Rosen
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

4.  PPD antigens and the diagnosis of mycobacterial diseases. A study of atypical mycobacterial disease in Oklahoma.

Authors:  L Fogan
Journal:  Arch Intern Med       Date:  1969-07

5.  Thin-layer chromatography of mycobacterial lipids as an aid to classification: technical improvements: mycobacterium avium, M. intracellulare (Battey bacilli).

Authors:  J Marks; P A Jenkins; W B Schaefer
Journal:  Tubercle       Date:  1971-09

6.  Clinical significance of nontuberculous mycobacteria. A bacteriological survey of Swedish strains isolated between 1973 and 1981.

Authors:  K Wickman
Journal:  Scand J Infect Dis       Date:  1986

7.  Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.

Authors:  S O'Brien; H Kantarjian; M Beran; T Smith; C Koller; E Estey; L E Robertson; S Lerner; M Keating
Journal:  Blood       Date:  1993-09-15       Impact factor: 22.113

8.  Epidemiology and clinical significance of nontuberculous mycobacteria in patients negative for human immunodeficiency virus in Switzerland.

Authors:  M Debrunner; M Salfinger; O Brändli; A von Graevenitz
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

9.  Nontuberculous mycobacterial disease. Experience in a southern California hospital.

Authors:  G J Gorse; R D Fairshter; G Friedly; L Dela Maza; G R Greene; T C Cesario
Journal:  Arch Intern Med       Date:  1983-02

10.  Disseminated atypical mycobacterial infection in patients with hairy cell leukemia.

Authors:  C Bennett; J Vardiman; H Golomb
Journal:  Am J Med       Date:  1986-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.